• Solia
  • Solia
  • Solia
  • Solia

    Solia S

    With more than 3 million implants worldwide,1 the Solia family is a complete portfolio of MR conditional active and passive fixation pacing leads. The Solia S lead is the only FDA-approved LBBAP lead backed by a prospective IDE clinical trial.2 

    The Solia family of pacing leads offers 5.6 F lead body diameter (6 F introducer) that is MR conditional, together with a polyurethane sleeve over a silicon insulator designed for reduced friction. Solia leads are approved for use with all BIOTRONIK ProMRI systems, giving physicians more options to accommodate varying patient anatomies.

    Category

    Lead Bradycardia

    Product Highlights

    Icon

    FDA Approved for LBBAP

    The Solia S lead is the only FDA approved LBBAP lead backed by a prospective IDE clinical trial. 
     

    Icon

    Implant with Confidence

    Low lead complication rate, high implant success rate and low, stable threshold at 12-month follow-up in LBBAP implants3,4

    Icon

    Drive Efficiency

    17% shorter lead implantation time for stylet-driven leads versus lumenless leads in LBBAP procedures.5

    Product Details

    • 5.6F lead body
    • Stylet-driven
    • Extendable/retractable helix
    • 10 mm distal collar-ring spacing
    • Polyurethane coating over silicone designed to reduce friction
    • 45 cm, 53 cm, and 60 cm lengths
    • Only lead to be FDA approved for LBBAP following a prospective clinical trial (BIO-CONDUCT, 2024)*
    • Unique BIOTRONIK fractal coating enlarges the bioeffective surface area for improved pacing and sensing6

     

    LBBAP Lead Delivery System
    Facilitating Physiologic Pacing For Your Patients

    Used in more than 80,000 patients worldwide and backed by more than 30 clinical studies to date,7 BIOTRONIK's Solia S lead and Selectra 3D catheter are the first and only FDA approved stylet-driven lead and dedicated delivery catheter combination for LBBAP.

    • Solia S is the only lead backed by a prospective IDE trial, demonstrating a high implant success rate of 95.7%.3
    • 17% shorter lead implantation time for stylet-driven leads vs. lumenless leads5
    • Less hassle with continuous electrical measurements and no need for special, costly tools.8

    *45 cm length not approved for LBBAP 

    Downloads & Related Links

    Manual Library

    Related Products

      Contact Us

      I prefer to be contacted by
      *Fields are mandatory.

      References

      1. Data on file. As of December 2024.
      2. BIOTRONIK Solia S technical manual. Abbott Ultipace, Tendril Lead technical manuals. Boston Scientific Ingevity+ lead technical manual. Medtronic SelectSecure 3830 technical manual.
      3. Liu, et al. Left bundle branch area pacing using a stylet-driven, retractable-helix lead: Short-term results from a prospective multicenter IDE trial (the BIO-CONDUCT study). Heart Rhythm. 2024 May 19:S1547-5271(24)02547-5. Epub ahead of print.
      4. De Pooter, et al. Initial experience of left bundle branch area pacing using stylet-driven pacing leads: A multicenter study. J Cardiovasc Electrophysiol. 2022; 33(7):1540-1549.
      5. Sritharan, et al. Procedural outcome and follow-up of stylet-driven leads compared with lumenless leads for left bundle branch area pacing. Europace. 2023 Oct 5;25(10) 
      6. Data on file.
      7. Data on file. As of July 2024.
      8. Burri H, Jastrzebski M, Cano Ó, et al. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023; 25(4): 1208-1236.